Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.10EUR
11:35am EST
Change (% chg)

€-1.10 (-1.48%)
Prev Close
€74.20
Open
€74.27
Day's High
€74.28
Day's Low
€72.95
Volume
2,443,884
Avg. Vol
2,487,737
52-wk High
€80.44
52-wk Low
€62.88

Select another date:

Tue, Feb 19 2019

Photo

Philippines revokes Sanofi's product license for dengue vaccine

MANILA The Philippines has permanently halted the sale, distribution and marketing of Sanofi's dengue vaccine in the country after the French drug maker failed to meet the directives of regulators.

Novo Nordisk, Sanofi must face lawsuit over insulin pricing: judge

A federal judge on Friday cleared the way for consumers to proceed with a proposed class action accusing drug manufacturers Sanofi SA and Novo Nordisk of fraudulently inflating prices for insulin.

PTAB sides with Sanofi in Dupixent fight with Amgen

The Patent Trial and Appeal Board on Thursday invalidated all claims of a patent that Amgen has accused Sanofi-Aventis and Regeneron Pharmaceuticals of infringing with their breakthrough biologic Dupixent.

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

NEW YORK, Feb 11 Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

France's Sanofi targets growth from new drugs after stronger quarter

PARIS French drugmaker Sanofi on Thursday pledged further increases in full-year profit helped by new drug launches and its reorganization efforts.

UPDATE 2-France's Sanofi targets growth from new drugs after stronger quarter

PARIS, Feb 7 French drugmaker Sanofi on Thursday pledged further increases in full-year profit helped by new drug launches and its reorganisation efforts.

REFILE-Sanofi's Genzyme lifts Q4 profits, expects more growth this year

PARIS, Feb 7 Sanofi posted slightly higher than expected fourth-quarter earnings on Thursday, helped by strong growth at its rare diseases Genzyme unit, and said it expected profits to rise again this year on the back of a revamped lineup of drugs.

Sanofi blood disorder drug wins FDA approval

The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Sanofi SA's drug to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments.

UPDATE 1-Sanofi blood disorder drug wins FDA approval

Feb 6 The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Sanofi SA's drug to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments.

Select another date: